Navigation Links
Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference

REDWOOD CITY, Calif., Jan 7, 2014 /PRNewswire/ -- Denny Lanfear, President and CEO of Coherus Biosciences, will present at the J.P. Morgan 32nd Annual Healthcare Conference on Wednesday, January 15 at the Westin St. Francis in San Francisco, CA., beginning at 4:30pm Pacific Standard Time. 


"Coherus' upcoming presentation at the conference marks an important milestone for our Company.  This event will introduce Coherus Biosciences to a worldwide healthcare investor audience and reflects the good progress the Company has made with products and partnerships," stated Mr. Lanfear. "To date, Coherus has filed INDs on three products and completed partnership agreements in Asia, Latin America and Europe with major biopharma firms while retaining US rights on all its products. We believe that this progress distinguishes Coherus as the leading independent pure play biosimilar company."

About Coherus Biosciences

Founded in 2010, Coherus Biosciences is a leading pure play biosimilar platform Company headquartered in the San Francisco Bay Area. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases. Our vision is to increase global patient access to high quality, life changing biologic medications.  Coherus' global partnerships include top tier BioPharma companies in Europe, Asia, and Latin America who are pursuing the integrated development and commercialization of products representing over $35 billion in current global sales.  From conceptualization to commercialization, Coherus' unique business model leverages a strategic consortium of key service providers aligned through ownership and shared incentives.  Through these partnerships, the Company has built a capital efficient infrastructure capable of taking products from cell lines to approved labels. To date, Coherus has raised approximately $125 million from equity and non-dilutive licensing fees.  Existing investors include KMG Capital, Lilly Ventures, Sofinnova and Venrock. 

Coherus Biosciences Contact
George Montgomery
(650) 649-3567

SOURCE Coherus BioSciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
2. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
3. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
4. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
6. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
7. Neurocrine Biosciences Reports First Quarter 2012 Results
8. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
9. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
10. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
11. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Post Your Comments:
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
Breaking Medicine News(10 mins):